Head to Head Comparison: Spectral AI (MDAI) & Its Peers

Spectral AI (NASDAQ:MDAI) is one of 228 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare Spectral AI to similar companies based on the strength of its earnings, institutional ownership, risk, dividends, profitability, analyst recommendations and valuation.

Profitability

This table compares Spectral AI and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-89.85%	N/A	-104.64%
Spectral AI Competitors	-563.96%	-136.63%	-25.35%

Insider & Institutional Ownership

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 48.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 56.7% of Spectral AI shares are owned by insiders. Comparatively, 15.4% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Spectral AI and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0	0	3	1	3.25
Spectral AI Competitors	1796	4748	8810	258	2.48

Spectral AI currently has a consensus price target of $4.50, suggesting a potential upside of 235.82%. As a group, “Surgical & medical instruments” companies have a potential upside of 20.02%. Given Spectral AI’s stronger consensus rating and higher possible upside, equities analysts clearly believe Spectral AI is more favorable than its rivals.

Valuation & Earnings

This table compares Spectral AI and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spectral AI	$22.53 million	-$20.85 million	-1.00
Spectral AI Competitors	$1.06 billion	$4.65 million	5.26

Spectral AI’s rivals have higher revenue and earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Spectral AI has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Spectral AI’s rivals have a beta of 0.54, suggesting that their average stock price is 46% less volatile than the S&P 500.

Summary

Spectral AI beats its rivals on 9 of the 13 factors compared.

Spectral AI Company Profile

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.